As we approach 2026, I wanted to quickly take a look at research I published in peer-reviewed journals last year. Here is the list:
- Shafrin JJadhav K, Warren C, Quddus S, Zawadzki N, Yang D, Damon A, Spurrier K, Batt K, Wei D. Chronic myeloid leukemia treatment intolerance places additional resource and economic burden on oncology practices in the United States. Journal of Medical Economics. 2025 Dec 31;28(1):2082-90.
- Wang S, Passos Chaves L, Olujohangbe O, Muthukrishnan S, Chaudhary A, Shafrin JQuantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures, Journal of Medical Economics. 2025 Dec 31;28(1):2057-70.
- Chen AJ, Docter JN, Garrison Jr LP, Goldman DP, Lakdawala DN, Liden B, Mulligan K, Peneva D, Shafrin JPhelps CE Response to the draft report of the Health Economics Methods Advisory (HEMA): “Defining appropriate benefits for economic evaluation of health care technologies”. October 20, 2025. https://schaeffer.usc.edu/wp-content/uploads/2025/10/HEMA-responses.Schaeffer-Center.pdf
- Mulve E, Shafrin JThan KS, Muthukrishnan S, Mutebi A, Chhibber A, Wang A, Alsharif A, Harb D, Gonzalez V, Quinlan S. Patient preferences for specific antibody properties for relapsed/refractory diffuse large B-cell lymphoma in the US. future oncology2025 Oct 20:1-2,
- Shafrin JZawadzki N, Marin M, Audhya I, Sedita LE, Kulkarni N, Klimchak AC. Caregiver risk preferences for delaying loss of ambulation in Duchenne muscular dystrophy in the United States. Current medical research and opinion2025 Aug 3;41(8):1499-509,
- Shafrin J, Kim J, Fajnor J, Thanh KS, Mearns ES, Kowal SL, Majda T, Hlavka JP. A generalized risk adjusted cost effectiveness (GRACE) economic model to measure the value of interventions delaying mobility loss in neurological conditions. value in health2025 August 21,
- Danny’s MD, Shafrin JLowry M, Korytowski B, Jordan S, Ryan D, Padda SK. Imaging utilization and treatment patterns of brain metastases in patients with non-small cell lung cancer: a SEER-Medicare and SEER database analysis. clinical lung cancer2025 July 29,
- El-Kersh K, Zawadzki N, Watzkar A, Zhang S, Dalal D, Lautsch D, Shafrin JA structured approach to the identification of disease analogs for pulmonary arterial hypertension, Managed Care and Specialty Pharmacy Journal2025 Sep;31(9):909-21,
- Shafrin JThan KS, Fajnor J, Kim J, Mearns ES, Koval SL, Majda T, Hlavka JP. Two approaches to measuring treatment value under uncertainty: estimating insurance value and risk preferences in neurology. Forum for Health Economics and Policy 2025 December 1 (Volume 28, Number 1, Pages 21-42). De Gruyter.
- Shafrin JFajnor J, Zhang S, Nicholls DE. Factors increasing utility management risk: A proof of concept. American Journal of Managed Care2025 Jun 1;31(6),
- Kim, Jaehong, Shanshan Wang, Moises Marin, Slaven Sikirica, Miriam Anderson, and jason shafrin“Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease,” Managed Care and Specialty Pharmacy Journal 31, no. 7 (2025): 641–650.
- Chung, Andrea P., Jason T. ShafrinSachin Vadgama, Kristen Hurley, Miguel-Angel Perales, Leonard C. Alsfeld, Sanjana Muthukrishnan, Anik R. Patel, Gunjan L. Shah, and Richard T. Maziarz. “Disparities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis.” blood advancement (2025).
- Shafrin, JasonSuhail Thahir, Alexa C. Klimchak, Ivana Audhya, Lauren E. Sedita, and John A. Romli. “Quantifying the altruism value for a rare pediatric disease: Duchenne muscular dystrophy.” American Journal of Managed Care 31, no. 5 (2025): 240–244.
- Shafrin, JasonShanshan Wang, Khoonish Sharma, Katherine Spurrier, and Robert J. Nordica. “Will the Institute for Clinical and Economic Review’s shared savings approach reduce value-based prices for the most serious diseases?”. value in health 28, no. 1 (2025): 25-30.
- Anyaduba, Uchechukwu Love, Oluwatosin Poet Orababa, Zion Faye, Nazia Rasheed, jason shafrinand Gregory Reardon. “Meta-analysis of recurrence-free survival or disease-free survival as potential surrogate endpoints for overall survival in esophageal cancer trials.” cancer report 8, no. 5 (2025): e70195.
- Shafrin, JasonShanshan Wang, Jaehong Kim, and Slaven Sikirica. “Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: budget impact analysis from a US payer perspective.” Managed Care and Specialty Pharmacy Journal 31, no. 4 (2025): 386–395.
- Tunis, Shawn R., jason shafrinKi-Sin Thanh, Melanie D. Whittington, Richard J. Wilke, and Murtuza Bharmal. “Use of Real-World Evidence in the Medicare Drug Price Negotiation Program: A Checklist for the Centers for Medicare and Medicaid Services and Manufacturers.” health experts 3, no. 3 (2025): qxaf030.
- Clayton, Dennis, jason shafrinGlorian P. Yen, Linsey Geevarghese, Yulin Shi, and Enem Waheed. “Retrospective claims analysis of complication rates in patients treated for paroxysmal nocturnal hemoglobinuria.” advances in therapy 42, no. 1 (2025): 500–509.
I was lucky to work with some amazing co-writers and I completed all this work in just one year. I’m excited to do more interesting research in 2026!
